Holen Sie sich die Stockscreener-App
67.75
1.53%
-1.0567
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Corient Private Wealth LP Makes New Investment in PTC Therapeutics, Inc. $PTCT - marketbeat.com
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Eastern Progress
Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT) - The Globe and Mail
Moore Capital Management LP Acquires 30,894 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Wellington Management Group LLP Raises Stake in PTC Therapeutics, Inc. $PTCT - marketbeat.com
Empowered Funds LLC Acquires Shares of 81,271 PTC Therapeutics, Inc. $PTCT - marketbeat.com
Legal & General Group Plc Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Palo Alto Investors LP Invests $74.95 Million in PTC Therapeutics, Inc. $PTCT - marketbeat.com
Hsbc Holdings PLC Takes $10.76 Million Position in PTC Therapeutics, Inc. $PTCT - marketbeat.com
PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments >PTCT - Moomoo
PTC Therapeutics director Michael Schmertzler sells $1.8m in shares - Investing.com
Michael Schmertzler Sells 12,500 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Jefferies Financial Group Inc. Purchases Shares of 1,357,042 PTC Therapeutics, Inc. $PTCT - marketbeat.com
Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT) - Sahm
PTC Therapeutics executives will speak at three September healthcare conferences - Stock Titan
The Manufacturers Life Insurance Company Takes $36.05 Million Position in PTC Therapeutics, Inc. $PTCT - marketbeat.com
Jupiter Topco LLC Makes New Investment in PTC Therapeutics, Inc. $PTCT - marketbeat.com
Ieq Capital LLC Acquires Shares of 19,611 PTC Therapeutics, Inc. $PTCT - marketbeat.com
435,691 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Parkman Healthcare Partners LLC - MarketBeat
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile - PR Newswire
PTC Therapeutics director Schmertzler disposes of $1.8m in stock - Investing.com
PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,500 Shares - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) director sells 25,000 shares in 10b5-1 trade - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Results - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920 - Sahm
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) CLO sells 2,813 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics (NASDAQ: PTCT) holder plans 50,000-share resale - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
PTC Therapeutics (NASDAQ: PTCT) insider lines up $201,692 share sale - Stock Titan
Price to earnings forward of PTC Therapeutics, Inc. – BX:P91 - TradingView
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal - MarketBeat
The week in pharma: action, reaction and insight – week to August 14, 2026 - The Pharma Letter
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Is Maintained at Overweight by Barclays - Moomoo
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Sahm
PTCT Maintained by Barclays -- Price Target Raised to $122 - GuruFocus
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - Dealbreaker
Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130 - Moomoo
PTC takes a chance on Sangamo’s Fabry disease gene therapy - BioPharma Dive
PTCT Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $109 - GuruFocus
PTC to Acquire Sangamo’s Fabry Disease Gene Therapy - Contract Pharma
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy - TipRanks
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale - BioSpace
Form 8K PTC Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
PTC to expand rare disease portfolio with ST-920 buy - The Pharma Letter
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction - Endpoints News
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners - The Business Journals
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 - Investing.com
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 By Investing.com - Investing.com Nigeria
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - PR Newswire
How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing - Stock Traders Daily
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment - simplywall.st
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):